Owlet Inc. (NYSE:OWLT) is a company focused on providing innovative health monitoring solutions for infants and children. Known for its flagship product, the Dream, and its Owlet360 subscriptions, the company aims to transition into a comprehensive pediatric health platform. Despite facing competition in the health tech space, Owlet continues to expand its product offerings and subscription services.
On March 6, 2026, Cowen & Co. maintained a "Buy" rating for Owlet, with the stock priced at $7.26. This decision to hold comes amid a backdrop of mixed financial performance. Owlet reported a fourth-quarter loss of 3 cents per share, which was better than the expected 13-cent loss. This indicates a positive trend in managing expenses and improving financial health.
Owlet's revenue for the fourth quarter increased by 29.6% year-over-year, reaching $26.6 million. This exceeded the consensus estimate of $25 million, driven by strong demand for the Dream product and Owlet360 subscriptions. Despite this growth, the stock experienced a decline in after-hours trading, reflecting market volatility and investor sentiment.
Looking forward, Owlet projects its 2026 revenues to be between $126 million and $130 million, suggesting a growth of 19% to 23% from 2025. The company is focusing on expanding its connected devices and increasing subscription adoption. However, profitability remains a challenge due to ongoing investments and external cost pressures, such as tariffs affecting product costs.
Currently, OWLT is priced at $7.26, having decreased by 38.21% or $4.49. The stock has fluctuated between $7 and $8.67 during the day, with a 52-week high of $16.94 and a low of $2.75. The market capitalization is approximately $116.17 million, with a trading volume of 2,566,300 shares on the NYSE.
